ArticlePLOS global public health2025
Optimising TB investments in Belarus, Moldova, Kyrgyz Republic, Tajikistan and Uzbekistan: An allocative efficiency analysis.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High rates of drug-resistant tuberculosis (TB) are a barrier to achieving End TB-strategy targets in Eastern Europe and Central Asia. This analysis collates results from five country-level modelling studies to identify priorities to reduce TB burden. Allocative efficiency studies were conducted in 2023 in Belarus, Kyrgyz Republic, Moldova, Tajikistan and Uzbekistan using the Optima TB model to determine the optimised distribution of funds to maximise health outcomes with given resources. A baseline scenario of continued 2022 spending was compared to scenarios with spending optimised across prevention, screening and treatment interventions to reduce TB incidence and deaths over 2024-2030. Modelled pulmonary TB incidence ranged from 25-119 per 100,000 population, and 14 - 43% of new/relapse TB cases were drug resistant. In all countries, optimizing current spending involved: expanding shorter treatment regimens (6-9 months) for drug-resistant-TB over standard regimens (18-20 months); reducing mass screening and mandatory testing and expanding community-based active case finding focused among populations at higher TB risk; and scaling-up TB preventive treatment. It was recommended to expand contact tracing in three countries and to improve cost-effectiveness in two countries by focusing on child household contacts first. With current spending optimised, pulmonary TB incidence was projected to decrease to 19 - 95 per 100,000 population by 2030, averting 1 - 13% of new/relapse TB cases and 1 - 18% of TB-related deaths from 2024-2030 compared to continued baseline spending. In three countries, optimised allocation of 150% of current spending had minimal additional epidemic impact. There are opportunities to reallocate TB funds more cost-effectively in Eastern Europe and Central Asia, but End TB targets may remain out of reach without new and prospective interventions.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.